TPWA
TGTX icon

Twin Peaks Wealth Advisors’s TG Therapeutics TGTX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-323
Closed -$10.7K – 1997
2026
Q1 		$10.7K Buy
+323
New +$9.63K ﹤0.01% 1029
2025
Q3 		– Sell
-385
Closed -$10.4K – 1924
2025
Q2 		$10.4K Buy
+385
New +$14.3K ﹤0.01% 914

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Twin Peaks Wealth Advisors's TGTX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 323 shares — an estimated $10.7K sold.

Twin Peaks Wealth Advisors first reported a position in TGTX in Q2 2025 and held it in 2 quarters. The position peaked at $10.7K in Q1 2026. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 323 TG Therapeutics shares in Q2 2026, an estimated $10.7K.
  • Twin Peaks Wealth Advisors first reported a position in TG Therapeutics in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's TG Therapeutics position peaked at $10.7K in Q1 2026.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.